Quidel Welcomes Newest Member of Triage Family

Quidel (San Diego, CA, USA) welcomed the newest member of the Triage family, the new Triage TOX Drug Screen, at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo held in Anaheim, California. The annual event held by the American Association for Clinical Chemistry (AACC) showcased the cutting edge science and technology shaping the future of laboratory medicine.

Quidel is a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems. The company’s products aid in the detection and diagnosis of several critical diseases and conditions, including influenza, respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal occult blood, among others. Quidel's recently acquired Triage system of tests comprises a comprehensive test menu that provides rapid, cost-effective treatment decisions at the point-of-care (POC), offering a diverse immunoassay menu in a variety of tests to provide diagnostic answers for quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I and qualitative TOX Drug Screen.


The Quidel Triage TOX Drug Screen is a fluorescence immunoassay to be used with the Quidel Triage MeterPro for the qualitative determination of the presence of drug and/or the major metabolites above the threshold concentrations of up to 10 distinct drug classes, including assays for acetaminophen/paracetamol, amphetamines, methamphetamines, barbiturates, benzodiazepines, cocaine, methadone, opiates, phencyclidine, THC and tricyclic antidepressants in urine.